Burning Rock Dx (NASDAQ: BNR and LSE: BNR) is a global diagnostics company focusing on applying next-generation sequencing (NGS) technology in precision oncology. Guided by the mission of “Guard Life via Science,” Burning Rock offers solutions covering the entire precision oncology development cycle through an internally developed NGS-based assay portfolio for both tissue and blood samples, along with a robust in-house database to help facilitate clinical trial studies and research. Burning Rock provides dedicated services to pharmaceutical partners, encompassing genomic data solutions, clinical trial solutions, precision patient recruitment, and companion diagnostics (CDx) development and commercialization.

Burning Rock’s diverse portfolio operates out of their two CLIA/CAP laboratories in China and the United States, allowing for global clinical trial support. Burning Rock has achieved two NMPA-approved IVD kits, four assays with CE marking, and a breakthrough device designation (BDD) received from both US FDA and China NMPA for multi-cancer detection blood test. Leveraging their robust NGS technology and extensive experience in pharmaceutical and project partnerships, Burning Rock stands as a global collaborator in driving advancements in precision oncology.